The nucleus paragigantocellularis and opioid withdrawal-like behavior.
Participation of the nucleus paragigantocellularis (PGi) in mediation of opioid withdrawal was examined in conscious, unrestrained, non-opioid-dependent rats, using electrical stimulation of the PGi. A characteristic series of behaviors, which resembled those seen during naloxone-precipitated withdrawal from dependence on the opioid agonist, butorphanol, was elicited during 30 min of PGi stimulation. Thus, the behavioral syndrome has been termed opioid withdrawal-like. Simultaneous microdialysis measurement of glutamate within the locus ceruleus indicated a positive correlation between extracellular glutamate concentrations and behavioral responses. Behavioral responses were inhibited by 50% during reverse dialysis perfusion of the locus ceruleus with the glutamate receptor antagonist, kynurenic acid, without any effect on glutamate concentrations. Thus, increases in locus ceruleus glutamate partially mediate opioid withdrawal-like behavior. Intracerebroventricular (i.c.v.) injections of the opioid antagonist, naloxone, or of the mu-selective (beta-funaltrexamine) or the delta-selective (naltrindole) opioid antagonists decreased, but did not abolish, stimulation-induced behavioral responses. Similar i.c.v. injections of the kappa-selective antagonist, nor-binaltorphimine, had no effect on behavioral responses to PGi stimulation. Activation of the PGi by electrical stimulation can elicit behaviors similar to those observed during opioid withdrawal. Moreover, additional levels of complexity are evident in the neuropharmacology of PGi stimulation-induced opioid withdrawal-like behavior.
Rockhold
R W
RW
Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Miss. 39216-4505, USA. rrockhold@pharmacology.umsmed.edu
Liu
N
N
Coleman
D
D
Commiskey
S
S
Shook
J
J
Ho
I K
IK
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D002077:Butorphanol / Q000009:adverse effects; D004558:Electric Stimulation; D005973:Glutamine / Q000378:metabolism; D008297:Male; D008526:Medulla Oblongata / Q000502:physiology*; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000009:adverse effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012965:Sodium Chloride / Q000494:pharmacology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D009435:Synaptic Transmission / Q000187:drug effects; D013997:Time Factors
D009292:Narcotic Antagonists; D009294:Narcotics; D005973:Glutamine; D009270:Naloxone; C051844:norbinaltorphimine; D012965:Sodium Chloride; D009271:Naltrexone; C024524:beta-funaltrexamine; C055382:naltrindole; D002077:Butorphanol